← Back to Screener
ScreenerNewsCompareWatchlist
VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesNewsCompareWatchlist
AnalyzeValuationTotal ReturnDCA CalculatorInsider Activity

AZTR logoAzitra, Inc.(AZTR)Earnings, Financials & Key Ratios

AZTR•AMEX
$0.24
$3M mkt cap·Price updated May 7, 2026
SectorHealthcareIndustryBiotechnologySub-IndustryMicrobiome and Phage Therapeutics
AboutAzitra, Inc., a pre-clinical biopharmaceutical company, focuses on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It is developing ATR-12, a genetically modified strain of S. epidermidis for treating Netherton syndrome, a skin disease; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor; and ATR-01, an engineered recombinant human filaggrin protein for treating ichthyosis vulgaris, a skin disease. The company was incorporated in 2014 and is based in Branford, Connecticut.Show more
  • Revenue$0-100.0%
  • EBITDA-$11M+99.9%
  • Net Income-$11M-22.2%
  • EPS (Diluted)-2.25-532.2%
  • ROE-0.58%+99.7%
  • ROIC-0.76%+100.0%
  • Debt/Equity0.11+13.9%
  • Interest Coverage-1445.45+99.8%
Technical→

AZTR Key Insights

Azitra, Inc. (AZTR) fundamental analysis — strengths, weaknesses & financial health based on data analysis

✓Strengths

  • ✓Trading at only 0.0x book value

✗Weaknesses

  • ✗Weak Piotroski F-Score: 1/9
  • ✗Shares diluted 100.0% in last year
  • ✗Trading more than 30% below 52-week high
  • ✗Low asset turnover indicates capital-intensive operations

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

AZTR Price & Volume

Azitra, Inc. (AZTR) stock price & volume — 10-year historical chart

Loading chart...

AZTR Growth Metrics

Azitra, Inc. (AZTR) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years-
5 Years-
3 Years-
TTM-100%

Profit CAGR

10 Years-
5 Years-
3 Years-
TTM-22.17%

EPS CAGR

10 Years-
5 Years-
3 Years-
TTM-98.09%

Return on Capital

10 Years-46359.42%
5 Years-46359.42%
3 Years-77186.29%
Last Year-0.55%

AZTR Peer Comparison

Azitra, Inc. (AZTR) competitors in Microbiome and Phage Therapeutics — business model, growth, and fundamentals comparison

Select Columns
Stock Universe
Valuation
Growth
Profitability
Financial Health
Dividends & Buybacks
Price Performance
Technical
Fundamentals ($)
Sector-Specific
CompanyMarket CapStock PriceP/E Ratio (TTM)Revenue Growth 1YNet MarginReturn on Equity (ROE)FCF YieldDebt / Equity
MIRM logoMIRMMirum Pharmaceuticals, Inc.Direct Competitor5.17B102.93-21954.74%-194.97%-289.33%1.02
SLDB logoSLDBSolid Biosciences Inc.Direct Competitor550.63M7.07-3.55-73.63%0.12
KRYS logoKRYSKrystal Biotech, Inc.Direct Competitor8.75B296.7043.3833.94%53.92%19.25%0.01
QNCX logoQNCXQuince Therapeutics, Inc.Direct Competitor7.24M1.30-0.08
SNDX logoSNDXSyndax Pharmaceuticals, Inc.Product Competitor1.81B20.54-6.246.28%-112.01%-256.66%5.36
ETON logoETONEton Pharmaceuticals, Inc.Product Competitor839M31.02-182.47104.94%-5.75%-18.84%0.35
PRAX logoPRAXPraxis Precision Medicines, Inc.Product Competitor9.63B333.28-24.72-100%-43.02%0.00
ACLX logoACLXArcellx, Inc.Product Competitor6.73B115.07-28.27-79.35%-10.27%-55.42%0.24

Compare AZTR vs Peers

Azitra, Inc. (AZTR) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs MIRM

Most directly comparable listed peer for AZTR.

Scale Benchmark

vs TMO

Larger-name benchmark to compare AZTR against a more recognizable public peer.

Peer Set

Compare Top 5

vs MIRM, SLDB, KRYS, QNCX

AZTR Income Statement

Azitra, Inc. (AZTR) annual income statement — 10-year revenue, gross profit & net income history

10Y historyFree accessUpdated daily
Line itemDec'21Dec'22Dec'23Dec'24Dec'25
Sales/Revenue110K284K686K7.5M0
Revenue Growth %-158.18%141.55%993.29%-100%
Cost of Goods Sold0000453.14K
COGS % of Revenue-----
Gross Profit
110K▲ 0%
284K▲ 158.2%
686K▲ 141.5%
7.5M▲ 993.3%
-453.14K▼ 106.0%
Gross Margin %100%100%100%100%-
Gross Profit Growth %-158.18%141.55%993.29%-106.04%
Operating Expenses9.33M9.74M8.14M10.99B10.51M
OpEx % of Revenue8483.14%3428.73%1186.09%146568.53%-
Selling, General & Admin3.95M3.64M4.49M6.27B6.13B
SG&A % of Revenue3592.14%1281.57%655%83590.16%-
Research & Development5.38M6.1M3.64M4.72B4.84B
R&D % of Revenue4891%2147.16%531.08%62978.37%-
Other Operating Expenses0000-10.96B
Operating Income
-9.22M▲ 0%
-9.45M▼ 2.5%
-7.45M▲ 21.2%
-10.99B▼ 147340.7%
-10.97M▲ 99.9%
Operating Margin %-8383.14%-3328.73%-1086.09%-146468.53%-
Operating Income Growth %--2.52%21.19%-147340.74%99.9%
EBITDA-9.14M-9.05M-7.02M-10.98B-10.51M
EBITDA Margin %-8306.07%-3185.78%-1024.05%-146462.56%-
EBITDA Growth %-0.97%22.36%-156265.79%99.9%
D&A (Non-Cash Add-back)84.77K405.98K425.55K448.24K453.14K
EBIT-8.87M-10.43M-11.1M-8.95M-10.94M
Net Interest Income-58.21K-247.07K-166.15K110.39K62.62K
Interest Income8.76K4.82K1.58K122.55K70.21K
Interest Expense66.97K251.89K167.73K12.16K7.59K
Other Income/Expense281.78K-1.23M-3.82M10.98B19.61K
Pretax Income
-8.94M▲ 0%
-10.68M▼ 19.5%
-11.27M▼ 5.5%
-8.96M▲ 20.5%
-10.95M▼ 22.2%
Pretax Margin %-8126.98%-3760.69%-1642.34%-119.45%-
Income Tax0017.31K9.03K8.32K
Effective Tax Rate %0%0%-0.15%-0.1%-0.08%
Net Income
-8.94M▲ 0%
-10.68M▼ 19.5%
-11.28M▼ 5.6%
-8.97M▲ 20.5%
-10.96M▼ 22.2%
Net Margin %-8126.98%-3760.69%-1644.87%-119.57%-
Net Income Growth %--19.47%-5.65%20.53%-22.17%
Net Income (Continuing)-8.94M-10.68M-11.28M-8.97M-10.96M
Discontinued Operations00000
Minority Interest00000
EPS (Diluted)
-3.33▲ 0%
-3.98▼ 19.5%
-4.20▼ 5.5%
-0.36▲ 91.5%
-2.25▼ 532.2%
EPS Growth %--19.47%-5.55%91.53%-532.28%
EPS (Basic)-3.33-3.98-7.34-0.36-2.25
Diluted Shares Outstanding60.49K60.49K34.51K567.57K4.87M
Basic Shares Outstanding60.49K60.49K34.51K567.57K4.87M
Dividend Payout Ratio-----

AZTR Balance Sheet

Azitra, Inc. (AZTR) balance sheet — assets, liabilities & shareholders' equity

Line itemDec'21Dec'22Dec'23Dec'24Dec'25
Total Current Assets8.49M4.14M2.54M5.23M3.02B
Cash & Short-Term Investments8.04M3.49M1.8M4.55M2.07B
Cash Only8.04M3.49M1.8M4.55M2.07B
Short-Term Investments00000
Accounts Receivable334.18K266.21K223.47K101.9K141.29K
Days Sales Outstanding1.11K342.13118.94.96-
Inventory00000
Days Inventory Outstanding-----
Other Current Assets0216.89K67.86K4.11K950.29M
Total Non-Current Assets1.71M3.03M2.58M2.13M2.01B
Property, Plant & Equipment946.68K1.96M1.58M1.21M962.08M
Fixed Asset Turnover0.12x0.14x0.43x6.22x-
Goodwill00000
Intangible Assets97.69K219.57K210.88K246.42K316.67M
Long-Term Investments00000
Other Non-Current Assets668.23K848.34K789.99K678.22K727.31M
Total Assets
10.2M▲ 0%
7.17M▼ 29.7%
5.12M▼ 28.6%
7.36M▲ 43.9%
5.03B▲ 68190.8%
Asset Turnover0.01x0.04x0.13x1.02x-
Asset Growth %--29.74%-28.63%43.85%68190.82%
Total Current Liabilities1.21M2.22M1.6M1.38M1.07B
Accounts Payable717.8K784.69K897.27K490.25K399.36K
Days Payables Outstanding----321.67
Short-Term Debt0000265.89M
Deferred Revenue (Current)15K156K000
Other Current Liabilities43.47K27.08K145.04K32.97K801.67M
Current Ratio7.02x1.86x1.58x3.80x2.83x
Quick Ratio7.02x1.86x1.58x3.80x2.83x
Cash Conversion Cycle-----
Total Non-Current Liabilities34.76M41.21M599.14K284.65K156.19M
Long-Term Debt992.02K6.6M00156.19M
Capital Lease Obligations0840.9K563.69K284.27K0
Deferred Tax Liabilities00000
Other Non-Current Liabilities33.77M33.76M35.45K381-156.19K
Total Liabilities35.97M43.43M2.2M1.66M1.22B
Total Debt992.02K7.73M885.95K555.51K422.08M
Net Debt-7.05M4.24M-910.04K-4M-1.65B
Debt / Equity--0.30x0.10x0.11x
Debt / EBITDA-----
Net Debt / EBITDA-----
Interest Coverage-137.70x-37.53x-44.42x-903383.22x-1445.45x
Total Equity
-25.77M▲ 0%
-36.26M▼ 40.7%
2.91M▲ 108.0%
5.7M▲ 95.6%
3.8B▲ 66608.2%
Equity Growth %--40.73%108.03%95.61%66608.16%
Book Value per Share-425.93-599.4184.4010.04779.97
Total Shareholders' Equity-25.77M-36.26M2.91M5.7M3.8B
Common Stock1041041.21K7631.07K
Retained Earnings-26.63M-37.31M-48.6M-57.57M-68.52M
Treasury Stock00000
Accumulated OCI00000
Minority Interest00000

AZTR Cash Flow Statement

Azitra, Inc. (AZTR) cash flow — operating, investing & free cash flow history

Line itemDec'21Dec'22Dec'23Dec'24Dec'25
Cash from Operations-8.07M-8.35M-7.36M-10.18M-11.22M
Operating CF Margin %-7333.96%-2939.95%-1073.23%-135.78%-
Operating CF Growth %--3.5%11.82%-38.32%-10.22%
Net Income-8.94M-10.68M-11.28M-8.97M-10.96B
Depreciation & Amortization84.77K405.98K425.55K448.24K453.14M
Stock-Based Compensation306.06K184.47K151.5K245.05K62.74M
Deferred Taxes00000
Other Non-Cash Items-164.86K1.43M4.1M-1.47M10.43B
Working Capital Changes646.35K310.76K-753.43K-441.72K-797.23K
Change in Receivables194.17K66.67K42.73K133.15K-44.72K
Change in Inventory00000
Change in Payables282.98K420.75K-68.68K-140.53K-500.32K
Cash from Investing-652.27K-336.76K-318.26K-379.25K-182.91K
Capital Expenditures-446.14K-33.1K-26.54K-8.57K-24.21M
CapEx % of Revenue405.58%11.66%3.87%0.11%-
Acquisitions00000
Investments-----
Other Investing-206.14K-303.66K-291.71K-370.68K24.03M
Cash from Financing992.86K4.13M5.98M13.32M8.92M
Debt Issued (Net)984.39K4.35M-7.39K-14.6K-112.64K
Equity Issued (Net)001000K1000K1000K
Dividends Paid00000
Share Repurchases00000
Other Financing8.47K-215.38K0-18.38K0
Net Change in Cash
-7.73M▲ 0%
-4.55M▲ 41.1%
-1.7M▲ 62.7%
2.76M▲ 262.6%
-2.49M▼ 190.1%
Free Cash Flow
-8.72M▲ 0%
-8.69M▲ 0.3%
-7.68M▲ 11.6%
-10.56M▼ 37.5%
-11.25B▼ 106388.2%
FCF Margin %-7926.94%-3060.03%-1119.63%-140.84%-
FCF Growth %-0.33%11.62%-37.53%-106388.24%
FCF per Share-144.14-143.66-222.53-18.61-2308.04
FCF Conversion (FCF/Net Income)0.90x0.78x0.65x1.14x1.02x
Interest Paid00000
Taxes Paid00000

AZTR Key Ratios

Azitra, Inc. (AZTR) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios

Metric20212022202320242025
Return on Equity (ROE)---387.34%-208.27%-0.58%
Return on Invested Capital (ROIC)---278.96%-445079.83%-0.76%
Gross Margin100%100%100%100%-
Net Margin-8126.98%-3760.69%-1644.87%-119.57%-
Debt / Equity--0.30x0.10x0.11x
Interest Coverage-137.70x-37.53x-44.42x-903383.22x-1445.45x
FCF Conversion0.90x0.78x0.65x1.14x1.02x
Revenue Growth-158.18%141.55%993.29%-100%

AZTR Frequently Asked Questions

Azitra, Inc. (AZTR) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

Azitra, Inc. (AZTR) saw revenue decline by 100.0% over the past year.

Azitra, Inc. (AZTR) reported a net loss of $11.0M for fiscal year 2025.

Dividend & Returns

Azitra, Inc. (AZTR) has a return on equity (ROE) of -0.6%. Negative ROE indicates the company is unprofitable.

Azitra, Inc. (AZTR) had negative free cash flow of $86.5M in fiscal year 2025, likely due to heavy capital investments.

Explore More AZTR

Azitra, Inc. (AZTR) financial analysis — history, returns, DCA and operating performance tools

Total Return Calculator

Historical returns with dividends reinvested

→

DCA Calculator

Dollar cost averaging vs lump sum

→

Dividend History

Yield, growth, payout safety & DRIP

→

Earnings History

EPS trends, net income & profitability

→

Price History

Long-term charts & historical price data

→

Revenue History

Sales growth patterns & revenue breakdown

→

Financial Ratios

30 years of market, efficiency and balance-sheet ratios

→

Valuation

DCF intrinsic value, peer multiples & estimates

→
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Patterns find ideas. Fundamentals build conviction.

Data updated daily

Quick Links

  • Home
  • Screener
  • Themes
  • Market Valuation
  • Valuation
  • Compare
  • Total Return
  • DCA Calculator
  • News
  • Insights
  • Methodology
  • How It Works
  • Profile

Popular Screens

  • VCP Hot
  • VCP Warm
  • Value Screens
  • Growth Screens
  • Momentum Screens
  • Technical Screens
  • Quality Screens

Community

  • Follow @VCPScanner on X

Get weekly stock ideas — free

© 2026 VCP Scanner. All rights reserved.
About·Privacy Policy·Terms of Service
Not financial advice. Do your own research.